Filing Details
- Accession Number:
- 0001609351-17-000109
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-10-24 16:16:09
- Reporting Period:
- 2017-10-20
- Accepted Time:
- 2017-10-24 16:16:09
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1609351 | Spark Therapeutics Inc. | ONCE | Biological Products, (No Disgnostic Substances) (2836) | 462654405 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1673528 | Daniel Faga | 3737 Market Street Suite 1300 Philadelphia PA 19104 | Chief Business Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2017-10-20 | 6,000 | $37.62 | 6,000 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-10-20 | 6,000 | $79.95 | 0 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2017-10-24 | 1,500 | $37.62 | 1,500 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2017-10-24 | 1,500 | $85.00 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2017-10-20 | 6,000 | $0.00 | 6,000 | $37.62 |
| Common Stock | Employee Stock Option (right to buy) | Disposition | 2017-10-24 | 1,500 | $0.00 | 1,500 | $37.62 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 131,500 | 2026-05-01 | No | 4 | M | Direct | |
| 130,000 | 2026-05-01 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 28, 2017.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.40 to $80.30, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
- 25% vested May 2, 2017 and the remainder vests in equal quarterly installments over the following three years.
Billionaire Hedge Funds
